CD47 and cholangiocarcinoma: have shown that CD47 promotes the growth and metastasis of cholangiocarcinoma (CCA); anti-CD47 mAb can inhibit the proliferation of CCA cells in primary and metastatic sites by inducing macrophage phagocytosis, and the interaction between CD47 and SIRPα is critical in this process; thus, targeting CD47 and SIRPα may be considered a novel precise therapeutic approach for preventing intrahepatic metastasis of CCA (112).